Singh R B, Niaz M A, Rastogi S S, Rastogi S
Heart Research Laboratory, Medical Hospital and Research Centre, Moradabad, India.
Am J Cardiol. 1996 Feb 1;77(4):232-6. doi: 10.1016/s0002-9149(97)89384-8.
In a randomized, double-blind, placebo-controlled trial, the effects of combined treatment with the antioxidant vitamins A (50,000 IU/day), vitamin C (1,000 mg/day), vitamin E (400 mg/day), and beta-carotene (25 mg/day) were compared for 28 days in 63 (intervention group) and 62 (placebo group) patients with suspected acute myocardial infarction. After treatment with antioxidants, the mean infarct size (creatine kinase and creatine kinase-MB gram equivalents) was significantly less in the antioxidant group than in the placebo group. Serum glutamic-oxaloacetic transaminase decreased by 45.6 IU/dl in the antioxidant group versus 25.8 IU/dl in the placebo group (p < 0.02). Cardiac enzyme lactate dehydrogenase increased slightly (88.6 IU/dl) in the antioxidant group compared with that in the placebo group (166.5 IU/dl) (p < 0.01). QRS score in the electrocardiogram was significantly less in the antioxidant than in the placebo group. The following levels increased in the antioxidant group versus the placebo group, respectively: plasma levels of vitamin E increased by 8.8 and 2.2 mumol/L (p < 0.01), vitamin C increased by 12.6 and 4.2 mumol/L (p < 0.01), beta-carotene increased by 0.28 and 0.06 mumol/L (p < 0.01), and vitamin A increased by 0.36 and 0.12 mumol/L (p < 0.01). Serum lipid peroxides decreased by 1.22 pmol/ml in antioxidant versus 0.22 pmol/ml in the placebo group (p < 0.01). Angina pectoris, total arrhythmias, and poor left ventricular function occurred less often in the antioxidant group. Cardiac end points were significantly less in the antioxidant group (20.6% vs 30.6%, respectively). These results suggest that combined treatment with antioxidant vitamins A, E, C, and beta-carotene in patients with recent acute myocardial infarction may be protective against cardiac necrosis and oxidative stress, and could be beneficial in preventing complications and cardiac event rate in such patients.
在一项随机、双盲、安慰剂对照试验中,对63例(干预组)和62例(安慰剂组)疑似急性心肌梗死患者进行了为期28天的研究,比较了抗氧化维生素A(50,000国际单位/天)、维生素C(1,000毫克/天)、维生素E(400毫克/天)和β-胡萝卜素(25毫克/天)联合治疗的效果。抗氧化剂治疗后,抗氧化剂组的平均梗死面积(肌酸激酶和肌酸激酶-MB克当量)显著小于安慰剂组。抗氧化剂组血清谷草转氨酶下降45.6国际单位/升,而安慰剂组下降25.8国际单位/升(p<0.02)。与安慰剂组相比,抗氧化剂组心脏酶乳酸脱氢酶略有升高(88.6国际单位/升)(p<0.01)。抗氧化剂组心电图的QRS评分显著低于安慰剂组。与安慰剂组相比,抗氧化剂组以下指标分别升高:维生素E血浆水平升高8.8和2.2微摩尔/升(p<0.01),维生素C升高12.6和4.2微摩尔/升(p<0.01),β-胡萝卜素升高0.28和0.06微摩尔/升(p<0.01),维生素A升高0.36和0.12微摩尔/升(p<0.01)。抗氧化剂组血清脂质过氧化物下降1.22皮摩尔/毫升,而安慰剂组下降0.22皮摩尔/毫升(p<0.01)。抗氧化剂组心绞痛、总心律失常和左心室功能不良的发生率较低。抗氧化剂组心脏终点事件显著较少(分别为20.6%对30.6%)。这些结果表明,近期急性心肌梗死患者联合使用抗氧化维生素A、E、C和β-胡萝卜素治疗可能对心脏坏死和氧化应激具有保护作用,并可能有助于预防此类患者的并发症和心脏事件发生率。